Tumour size and histologic grading in node negative breast cancer: Prognostic and therapeutic implications;Tumorstørrelse og histologisk gradering ved cancer mammae stadium 1: Prognostisk og terapeutisk betydning

Tidsskrift for den Norske Laegeforening

Volumn 116, Issue 2, 1996, Pages 222-225

  Gundersen, Stein ^a   Bøhler, Per ^a   Hannisdal, Einar ^a   Høst, Herman ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; FEMALE; HUMAN; MASTECTOMY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREOPERATIVE CARE; PROGNOSIS; RISK FACTOR;

AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK FACTORS;

EID: 0030594006     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15, 71-85.
2. McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin MP, Clark GM. Prognosis and treatment decisions in axillary node-negative breast cancer patients. Cancer Supplement 1992; 70: 1775-81.
3. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 1206-19.
4. Ottestad L, Pettersen EO, Nesland JM, Hannisdal H, Fosså SD, Tveit KM. Flow cytometric DNA analysis as prognostic factor in human breast carcinoma. Pathol Res Pract 1993; 189: 405-10.
5. Høst H, Brennhovd IO, Loeb M. Postoperative radiotherapy in breast cancer - long-term results from the Oslo study. Int J Radiat Oncol Biol Phys 1986; 12: 727-32.
6. Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH et al, red. TNM atlas. 3. utg. Berlin: Springer-Verlag, 1992.
7. Patey DH, Scarff RW. Histology in the prognosis of carcinoma of the breast. Lancet 1928; 1: 801-4.
8. Bloom HJG, Richardson WW. Histologic grading and prognosis in breast cancer Br J Cancer 1957; 11: 359-77.
9. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer, experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
10. Page DL. Prognosis and breast cancer. Am J Surg Pathol 1991; 15: 334-49.
11. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SE et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-39.
12. Dixon WJ, Brown MB, Engelman L, Jennrich RI, red. BMDP statistical software manual. Berkeley: University of California Press, 1990.
13. Stål O, Dufmats M, Hatschek T. S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 1993; 11: 1717-22.
14. Børresen A-L, Ottestad L, Gaustad A, Andersen TI, Heikkilæ R, Jahnsen T et al. Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 1990; 62: 585-90.
15. Allred DC, Clark GM, Tandon AK. HER-2/ neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-5.
16. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 1988; 61: 420-7.
17. Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP. Evaluation of cell proliferation in breast carcinoma: comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis and mitotic count. Cancer 1990; 65: 1180-4.
18. Meyer JS. An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989; 64: 1914-21.
19. Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbriglia JE, Levy WM. Interobserver reproducibility of histopathologic features in stage II breast cancer. Breast Cancer Res Treat 1985; 5: 3-10.
20. Davis BW, Gelberg RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastases. Cancer 1986, 58: 2662-70.
21. Rosner D, Lane W. Should all patients with node-negative breast cancer receive adjuvant therapy? Cancer 1991; 68: 1482-94.
22. Contesso G, Mouriesse H, Friedman S, Genin J, Sarazzin D, Rouesse J. The importance of histologie grade in long-term prognosis of breast cancer. A study of 1010 patients uniformly treated at the Institute Gustave Roussy. J Clin Oncol 1987; 5: 1378-86.
23. Dalton LW, Page DL, Dupont WD. Histologie grading of breast carcinoma. A reproducibility study. Cancer 1994; 73: 2765-70.